SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 140 participants.

Also called NCT06373601

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06373601
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06373601. Randomized; no masking; primary purpose treatment. Start 2024-09-05 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
Acronym
SPAGO
Condition
Stenosis Coronary
Condition
Coronary Artery Lesion
Intervention (Device)
sirolimus-eluting balloon (Selution)
Intervention (Device)
paclitaxel-eluting balloon (SeQuent Please Neo)
Lead sponsor
Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS (class: other)

Record details

Record id
cardio:ct-nct06373601
Content hash
9a0524cfe5ffb8c9453132a6ab0fa659dd438fbe3e65f49cbc730e19de1115f1